Company Description

Moonwalk Biosciences is developing first-in-class adipose-targeted RNA interference (RNAi) medicines for obesity and cardiometabolic diseases. The Company's proprietary AI-enabled discovery platform integrates human genetics, epigenomics and multi-omics with adipose-selective siRNA chemistry to identify and validate novel therapeutic targets involved in adipose biology, without affecting appetite.